Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Small Cell Lung Carcinoma 4Ovarian Neoplasms 3Stomach Neoplasms 2Solid Tumor 2Gastric Adenocarcinoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Two Different Treatment Methods 1Squamous Cell Carcinoma of Head and Neck 1Osteosarcoma 1Mucosal Melanoma 1Melanoma 1Immunotherapy Gastrict Cancer 1Immunotherapy 1HER-2 Negatived Gastric Cancer 1Carcinoma, Ovarian Epithelial 1Advanced Triple Negative Breast Cancer 1Advanced Metastatic Gastric Cancer 1Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction 1Advanced Gastric Cancer 1Advanced Gastric Adenocarcinoma 1Advanced Esophagus Cancer 1Adenocarcinoma of Lung 1

Interventions

Interleukin-2 4Nivolumab 3Melphalan 3pembrolizumab 2tremelimumab 1tislelizumab 1fludarabine 1encorafenib 1binimetinib 1apatinib 1Tramadol 1Technetium 1Surgical Procedures, Operative 1Metastasectomy 1Ipilimumab 1Immunotherapy 1Ibuprofen 1Fecal Microbiota Transplantation 1FMT protocol 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Melanoma × apatinib × Clear all
NCT03383237 2017-12-27

Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Henan Cancer Hospital

Phase 2 Unknown
20 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡